Molecular pathways: Regulation of metabolism by RB

Clinical Cancer Research

Volumn 18, Issue 22, 2012, Pages 6096-6100

  Clem, Brian F ^a   Chesney, Jason ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

AMINO ACID METABOLISM; ARTICLE; BIOGENESIS; CARCINOGENESIS; CELL CYCLE REGULATION; GLYCOLYSIS; HUMAN; METABOLIC REGULATION; MITOCHONDRIAL GLUTAMINOLYSIS; MOLECULAR PATHOLOGY; NEOPLASM; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING;

ANIMALS; CARBOHYDRATE METABOLISM; GLUCOSE; GLUTAMINE; HUMANS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NEOPLASMS; RETINOBLASTOMA PROTEIN;

EID: 84869228046     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3164     Document Type: Article

References (59)

1. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
2. Strong LC, Riccardi VM, Ferrell RE, Sparkes RS. Familial retinoblastoma and chromosome 13 deletion transmitted via an insertional translocation. Science 1981;213:1501-3. (Pubitemid 11031232)
3. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987;235:1394-9. (Pubitemid 17041661)
4. Goodrich DW, Lee WH. Molecular characterization of the retinoblastoma susceptibility gene. Biochim Biophys Acta 1993;1155:43-61. (Pubitemid 23163750)
5. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008;8:671-82.
6. Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 2008;8:714-24.
7. Huang HJ, Yee JK, Shew JY, Chen PL, Bookstein R, Friedmann T, et al. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 1988;242:1563-6. (Pubitemid 19023702)
8. Paternot S, Bockstaele L, Bisteau X, Kooken H, Coulonval K, Roger PP. Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle 2010;9:689-99.
9. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009;9:785-97.
10. Goodrich DW, Wang NP, Qian YW, Lee EY, Lee WH. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 1991;67:293-302. (Pubitemid 121001445)
11. Brehm A, Kouzarides T. Retinoblastoma protein meets chromatin. Trends Biochem Sci 1999;24:142-5. (Pubitemid 29222713)
12. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998;12:2245-62. (Pubitemid 28371346)
13. Harbour JW, Dean DC. Chromatin remodeling and Rb activity. Curr Opin Cell Biol 2000;12:685-9.
14. Nevins JR. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ 1998;9:585-93. (Pubitemid 28367248)
15. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002;3:11-20. (Pubitemid 135709914)
16. Anderson MM, Chen J, Cole CN, Conrad SE. Activation of the human thymidine kinase (TK) promoter by simian virus 40 large T antigen requires both theT antigenpRbfamily-bindingdomain andTKpromoter sequences resembling E2F-binding sites. J Virol 1996;70:6304-13. (Pubitemid 26266850)
17. Dou QP, Markell PJ, Pardee AB. Thymidine kinase transcription is regulated at G1/S phase by a complex that contains retinoblastomalike protein and a cdc2 kinase. Proc Natl Acad Sci U S A 1992;89:3256-60.
18. Dou QP, Zhao S, Levin AH, Wang J, Helin K, Pardee AB. G1/S-regulated E2F-containing protein complexes bind to the mouse thymidine kinase gene promoter. J Biol Chem 1994;269:1306-13. (Pubitemid 24032524)
19. Fry CJ, Pearson A, Malinowski E, Bartley SM, Greenblatt J, Farnham PJ. Activation of the murine dihydrofolate reductase promoter by E2F1. A requirement for CBP recruitment. J Biol Chem 1999;274:15883-91.
20. Jensen DE, Black AR, Swick AG, Azizkhan JC. Distinct roles for Sp1 and E2F sites in the growth/cell cycle regulation of theDHFR promoter. J Cell Biochem 1997;67:24-31. (Pubitemid 27430320)
21. Luo RX, Postigo AA, Dean DC. Rb interacts with histone deacetylase to repress transcription. Cell 1998;92:463-73. (Pubitemid 28101110)
22. Tommasi S, Pfeifer GP. Constitutive protection of E2F recognition sequences in the human thymidine kinase promoter during cell cycle progression. J Biol Chem 1997;272:30483-90. (Pubitemid 27512260)
23. Wade M, Kowalik TF, Mudryj M, Huang ES, Azizkhan JC. E2F mediates dihydrofolate reductase promoter activation and multiprotein complex formation in human cytomegalovirus infection. Mol Cell Biol 1992;12:4364-74.
24. Beemer FA, Vlug AM, Rijksen G, Hamburg A, Staal GE. Characterization of some glycolytic enzymes from human retina and retinoblastoma. Cancer Res 1982;42:4228-32. (Pubitemid 13198588)
25. Dias PL, Shanmuganathan SS, Rajaratnam M. Lactic dehydrogenase activity of aqueous humour in retinoblastoma. Br J Ophthalmol 1971;55:130- 2.
26. Kim JW, Zeller KI, Wang Y, Jegga AG, Aronow BJ, O'Donnell KA, et al. Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol 2004;24:5923-36. (Pubitemid 38787976)
27. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000;275:21797-800. (Pubitemid 30621745)
28. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A 1997;94:6658-63. (Pubitemid 27281920)
29. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009;15:6479-83.
30. Lee KY, LadhaMH,McMahon C,Ewen ME. The retinoblastoma protein is linked to the activation of Ras. Mol Cell Biol 1999;19:7724-32. (Pubitemid 29493436)
31. Raptis L, Brownell HL, Corbley MJ, Wood KW, Wang D, Haliotis T. Cellular ras gene activity is required for full neoplastic transformation by the large tumor antigen of SV40. Cell Growth Differ 1997;8:891-901. (Pubitemid 27355462)
32. Chesney J, Telang S. Regulation of glycolytic and mitochondrial metabolism by Ras. Curr Pharm Biotechnol. 2012 Jun 1 [Epub ahead of print].
33. Telang S, Yalcin A, Clem AL, Bucala R, Lane AN, Eaton JW, et al. Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene 2006;25:7225-34. (Pubitemid 44809088)
34. Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J Biol Chem 1997;272:17269-75. (Pubitemid 27311150)
35. El-Naggar S, Liu Y, Dean DC. Mutation of the Rb1 pathway leads to overexpression of mTor, constitutive phosphorylation of Akt on serine 473, resistance to anoikis, and a block in c-Raf activation. Mol Cell Biol 2009;29:5710-7.
36. Emerling BM, Weinberg F, Liu JL, Mak TW, Chandel NS. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci U S A 2008;105:2622-7. (Pubitemid 351520563)
37. Holness MJ, Sugden MC. Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochem Soc Trans 2003;31:1143-51. (Pubitemid 38030927)
38. Sugden MC, Holness MJ. Mechanisms underlying regulation of the expression and activities of the mammalian pyruvate dehydrogenase kinases. Arch Physiol Biochem 2006;112:139-49. (Pubitemid 44871041)
39. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3:177-85.
40. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007;27:7381-93. (Pubitemid 350033646)
41. Blanchet E, Annicotte JS, Lagarrigue S, Aguilar V, Clape C, Chavey C, et al. E2F transcription factor-1 regulates oxidative metabolism. Nat Cell Biol 2011;13:1146-52.
42. Hsieh MC, Das D, Sambandam N, Zhang MQ, Nahle Z. Regulation of the PDK4 isozyme by the Rb-E2F1 complex. J Biol Chem 2008;283:27410-7.
43. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2009;29:313-24.
44. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007;104:19345-50.
45. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008;18:54-61. (Pubitemid 351694453)
46. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010;35:427-33.
47. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 2012;15:110-21.
48. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009;458:762-5.
49. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 2008;105:18782-7.
50. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007;178:93-105. (Pubitemid 47026405)
51. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature 2011;476:163-9.
52. Reynolds M, Clem BF. Unpublished observations.
53. Dali-Youcef N, Mataki C, Coste A, Messaddeq N, Giroud S, Blanc S, et al. Adipose tissue-specific inactivation of the retinoblastoma protein protects against diabesity because of increased energy expenditure. Proc Natl Acad Sci U S A 2007;104:10703-8. (Pubitemid 47185728)
54. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 2010;107:2037-42.
55. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009;325:1555-9.
56. Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther 2008;7:110-20.
57. Bonomi P, Finkelstein D, Chang A. Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1994;17:215-7. (Pubitemid 24160610)
58. Robinson MM, McBryant SJ, Tsukamoto T, Rojas C, Ferraris DV, Hamilton SK, et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sul fide (BPTES). Biochem J 2007;406:407-14. (Pubitemid 47425447)
59. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010;18:207-19.